A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?

BACKGROUND: Ovarian cancer (OC) is the sixth most common cancer in women. Currently, carboplatin/paclitaxel ± bevacizumab is the cornerstone of front-line treatment. Conversely, the therapeutic options for recurrent or progressive disease are not well defined. For platinum-sensitive patients the bes...

Descripción completa

Detalles Bibliográficos
Autores principales: Staropoli, Nicoletta, Ciliberto, Domenico, Botta, Cirino, Fiorillo, Lucia, Gualtieri, Simona, Salvino, Angela, Tassone, Pierfrancesco, Tagliaferri, Pierosandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599392/
https://www.ncbi.nlm.nih.gov/pubmed/23388584
http://dx.doi.org/10.1186/1757-2215-6-10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599392/
https://www.ncbi.nlm.nih.gov/pubmed/23388584
http://dx.doi.org/10.1186/1757-2215-6-10

Ejemplares similares